Business Description
Catalyst Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US14888U1016
Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 134.78 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 16.41 | |||||
| Beneish M-Score | -3.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 46.2 | |||||
| 3-Year EBITDA Growth Rate | 39.2 | |||||
| 3-Year EPS without NRI Growth Rate | -6.1 | |||||
| 3-Year FCF Growth Rate | 8.7 | |||||
| 3-Year Book Growth Rate | 30.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 44.01 | |||||
| Future 3-5Y Total Revenue Growth Rate | 17.95 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.44 | |||||
| 9-Day RSI | 48.63 | |||||
| 14-Day RSI | 49.98 | |||||
| 6-1 Month Momentum % | 42.1 | |||||
| 12-1 Month Momentum % | 38.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.11 | |||||
| Quick Ratio | 4.92 | |||||
| Cash Ratio | 4.2 | |||||
| Days Inventory | 95.77 | |||||
| Days Sales Outstanding | 43.99 | |||||
| Days Payable | 56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | -5.45 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.32 | |||||
| Operating Margin % | 37.78 | |||||
| Net Margin % | 31.01 | |||||
| FCF Margin % | 48.13 | |||||
| ROE % | 27.81 | |||||
| ROA % | 23.73 | |||||
| ROIC % | 52.33 | |||||
| ROC (Joel Greenblatt) % | 1452.29 | |||||
| ROCE % | 33.49 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.31 | |||||
| Forward PE Ratio | 13.61 | |||||
| PE Ratio without NRI | 18.27 | |||||
| Shiller PE Ratio | 85.26 | |||||
| Price-to-Owner-Earnings | 15.93 | |||||
| PS Ratio | 5.71 | |||||
| PB Ratio | 3.9 | |||||
| Price-to-Tangible-Book | 5.21 | |||||
| Price-to-Free-Cash-Flow | 11.87 | |||||
| Price-to-Operating-Cash-Flow | 11.72 | |||||
| EV-to-EBIT | 12.36 | |||||
| EV-to-Forward-EBIT | 7.58 | |||||
| EV-to-EBITDA | 10.17 | |||||
| EV-to-Revenue | 4.67 | |||||
| EV-to-Forward-Revenue | 3.67 | |||||
| EV-to-FCF | 9.46 | |||||
| Price-to-Projected-FCF | 2.18 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.73 | |||||
| Price-to-Graham-Number | 2.05 | |||||
| Price-to-Net-Current-Asset-Value | 6.02 | |||||
| Price-to-Net-Cash | 7.77 | |||||
| Earnings Yield (Greenblatt) % | 8.09 | |||||
| FCF Yield % | 8.43 | |||||
| Forward Rate of Return (Yacktman) % | 23.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Catalyst Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 421.971 | ||
| EPS (TTM) (€) | 1.081 | ||
| Beta | 1.01 | ||
| Volatility % | 36.28 | ||
| 14-Day RSI | 49.98 | ||
| 14-Day ATR (€) | 0.416105 | ||
| 20-Day SMA (€) | 20.7 | ||
| 12-1 Month Momentum % | 38.89 | ||
| 52-Week Range (€) | 12.185 - 22.36 | ||
| Shares Outstanding (Mil) | 119.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Catalyst Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Catalyst Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Catalyst Pharmaceuticals Inc Frequently Asked Questions
What is Catalyst Pharmaceuticals Inc(STU:CN2)'s stock price today?
The current price of STU:CN2 is €20.36. The 52 week high of STU:CN2 is €22.36 and 52 week low is €12.19.
When is next earnings date of Catalyst Pharmaceuticals Inc(STU:CN2)?
The next earnings date of Catalyst Pharmaceuticals Inc(STU:CN2) is 2025-02-28 Est..
Does Catalyst Pharmaceuticals Inc(STU:CN2) pay dividends? If so, how much?
Catalyst Pharmaceuticals Inc(STU:CN2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers